<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/7369E051-ECFC-4808-A044-651879C318D1"><gtr:id>7369E051-ECFC-4808-A044-651879C318D1</gtr:id><gtr:name>MRC Cancer Cell Unit</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB2 2XZ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7369E051-ECFC-4808-A044-651879C318D1"><gtr:id>7369E051-ECFC-4808-A044-651879C318D1</gtr:id><gtr:name>MRC Cancer Cell Unit</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB2 2XZ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/415AF196-6CDB-4F5C-958F-5C9D12FCB76A"><gtr:id>415AF196-6CDB-4F5C-958F-5C9D12FCB76A</gtr:id><gtr:firstName>Guillermo</gtr:firstName><gtr:surname>de la Cueva Mendez</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U105365008"><gtr:id>3D4EF6C1-401A-4F37-94B8-342D416EC62B</gtr:id><gtr:title>Toxin-Antitoxin pairs in Biotechnology and Therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U105365008</gtr:grantReference><gtr:abstractText>Collateral damage to normal cells is a major limitation to the success of anticancer treatments, and our research aims to investigate therapeutic alternatives to minimize this complication. So far, we have focused on two strategies: i) exploiting genetic differences between cancer and normal cells to confer selective protection from the cytotoxic effect of endoribonuclease Kid to normal cells, using antitoxin Kis and, ii) improving drug-encapsulating systems that allow selective systemic delivery of anticancer agents to cancer cells in vivo. In the past five years we have completed our characterization of the mode of action, specificity and function of Kid, an understanding that is essential for its correct biotechnological/therapeutic exploitation. We have also obtained proof-of-principle for our proposal that toxin Kid and antitoxin Kis can be used to achieve selective killing of specific cancer cells. One of these strategies is particularly attractive, as it may not need DNA transfer to target cells for its implementation. Additionally, we have worked on an encapsulating agent that can be used to deliver small drugs, nucleic acids and proteins to cancer cells in vivo. We plan now to exploit this system to deliver anticancer agents and imaging probes to cancer cells in vivo, and to test their performance in both treatment and non-invasive imaging of tumors. Finally, based on our previous results, we are generating a novel tool using Kid and Kis, which we will use to identify molecular determinants of drug sensitivity in cancer cells. This should help to develop new anticancer drugs, more effective and less toxic to normal cells.</gtr:abstractText><gtr:technicalSummary>Collateral damage to normal cells is a major limitation to the success of anticancer treatments, and our research aims to investigate therapeutic alternatives to minimize this complication. So far, we have focused on two strategies: i) exploiting genetic differences between cancer and normal cells to confer selective protection from the cytotoxic effect of endoribonuclease Kid to normal cells, using antitoxin Kis and, ii) improving drug-encapsulating systems that allow selective systemic delivery of anticancer agents to cancer cells in vivo. In the past five years we have completed our characterization of the mode of action, specificity and function of Kid, an understanding that is essential for its correct biotechnological/therapeutic exploitation. We have also obtained proof-of-principle for our proposal that toxin Kid and antitoxin Kis can be used to achieve selective killing of specific cancer cells. One of these strategies is particularly attractive, as it may not need DNA transfer to target cells for its implementation. Additionally, we have worked on an encapsulating agent that can be used to deliver small drugs, nucleic acids and proteins to cancer cells in vivo. We plan now to exploit this system to deliver anticancer agents and imaging probes to cancer cells in vivo, and to test their performance in both treatment and non-invasive imaging of tumors. Finally, based on our previous results, we are generating a novel tool using Kid and Kis, which we will use to identify molecular determinants of drug sensitivity in cancer cells. This should help to develop new anticancer drugs, more effective and less toxic to normal cells.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2001-06-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2177821</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8A01ED30-5FF9-4C2C-A453-9DEE253225C1</gtr:id><gtr:title>Toxin Kid uncouples DNA replication and cell division to enforce retention of plasmid R1 in Escherichia coli cells.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/425fcd58468ef75dd82cf3f20825dc0d"><gtr:id>425fcd58468ef75dd82cf3f20825dc0d</gtr:id><gtr:otherNames>Pimentel B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_540e181e181a99c59</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>677F9C21-328B-4BCF-9254-54228E3CF545</gtr:id><gtr:title>Retinoic acid-induced glandular differentiation of the oesophagus.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/066d29ad97b024c2a8ff7b1a2a2e0ede"><gtr:id>066d29ad97b024c2a8ff7b1a2a2e0ede</gtr:id><gtr:otherNames>Chang CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>A78E1617D9A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB89B000-62F8-4820-BDDF-FCD0BB0017D1</gtr:id><gtr:title>Repurposing a Prokaryotic Toxin-Antitoxin System for the Selective Killing of Oncogenically Stressed Human Cells.</gtr:title><gtr:parentPublicationTitle>ACS synthetic biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eaa428eb7db47bbe5f3ab15afba7119f"><gtr:id>eaa428eb7db47bbe5f3ab15afba7119f</gtr:id><gtr:otherNames>Preston MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2161-5063</gtr:issn><gtr:outcomeId>585d365cd2b5d3.68795682</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A68CCAA6-29DC-431F-8B39-42D6A6465C27</gtr:id><gtr:title>Gene and cell survival: lessons from prokaryotic plasmid R1.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f7ff271602a9c8f14de4659c474cac0"><gtr:id>9f7ff271602a9c8f14de4659c474cac0</gtr:id><gtr:otherNames>de la Cueva-M?ndez G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>2AC0078C9D6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9CC2611-8D77-40E8-9DB6-323CFE8AA027</gtr:id><gtr:title>New insights into the chromosome cycle. Conference on the Replication &amp;amp; Segregation of Chromosomes.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da2792e0c554285d6b8e8bb2e359a193"><gtr:id>da2792e0c554285d6b8e8bb2e359a193</gtr:id><gtr:otherNames>de la Cueva-Mendez G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>37B6D9305BF</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U105365008</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>